MiRNAs-based therapy for Cardiovascular and metabolic disorders: MiRNA-138 improves cardiovascular and metabolic abnormalities via down regulation of its target gene, 8/July/2014, 7.30 am

Insights into extending the longevity and survial of Haematopoietic stem cells: The epithelial-mesenchymal transition protein Snai1/Snail1 increases the longevity of hematopoietic stem cells via up regulation of its target gene, Genome-2-Bio-Medicine Discovery Center, 08/July/2014, 7.23 am
July 8, 2014
Natural product-based therapeutics for Inflammatory cardiac disease: Resveratrol, a longevity promoting drug, inhibits Inflammatory dilated cardiomyopathy (DCMi) via down regulation of its target gene, 6/July/2014, 8.00 am
July 8, 2014
Show all

A study from the Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; and PRESTO, Japan Science and Technology Agency, Saitama, Japan has reported that “Inhibition of Endothelial p53 Improves Metabolic Abnormalities..”

This study was published in the June 12, 2014 Cell Reports by Prof. Minamino TYokoyama and others from the Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; and PRESTO, Japan Science and Technology Agency, Saitama, Japan.

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: MiRNAs-based therapy for Cardiovascular and metabolic disorders: MiRNA-138 improves cardiovascular and metabolic abnormalities via down regulation of its target gene.  This study suggests that miR-138, by down regulating its target gene, it may improve cardiovascular and metabolic abnormalities. Together, this study suggests that pharmacological formulations containing “miR-138 or its small molecule activators”  can be used to treat  cardiovascular and metabolic abnormalities.

Idea Proposed/Formulated by: Dr L Boominathan PhD

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Courtesy: When you cite drop us a line at info@genomediscovery.org

CitationBoominathan, MiRNAs-based therapy for Cardiovascular and metabolic disorders: MiRNA-138 improves cardiovascular and metabolic abnormalities via down regulation of its target gene, 8/July/2014, 7.30 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

*Research cooperation

Comments are closed.